| Literature DB >> 25848635 |
Colleen M McCullough1, Jason J Wang1, Amanda S Parsons2, Sarah C Shih1.
Abstract
INTRODUCTION: To date, little research has been published on the impact that the transition from paper-based record keeping to the use of electronic health records (EHR) has on performance on clinical quality measures. This study examines whether small, independent medical practices improved in their performance on nine clinical quality measures soon after adopting EHRs.Entities:
Year: 2015 PMID: 25848635 PMCID: PMC4371508 DOI: 10.13063/2327-9214.1131
Source DB: PubMed Journal: EGEMS (Wash DC) ISSN: 2327-9214
Characteristics of Patients Whose Charts Were Reviewed for the Study
| Number of months in period | 12.0 (0.0) | 12.0 (0.0) | 11.0 (4.3) | 6.0 (0.0) |
| Total number of patient charts reviewed | 1,405 | 2,342 | 3,225 | 2,514 |
| Number of charts reviewed per practice | 54.0 (36.4) | 66.9 (39.4) | 94.9 (17.1) | 73.9 (14.4) |
| Patient age (in years) | 51.5 (4.3) | 51.8 (4.5) | 47.3 (5.3) | 49.0 (5.8) |
| Number of visits in the reporting period | 3.8 (1.7) | 3.9 (1.5) | 3.4 (1.4) | 2.7 (1.1) |
| Percent female | 55.0 (21.1) | 56.1 (16.2) | 60.5 (10.8) | 60.7 (11.3) |
| Diabetes | 14.1 (12.2) | 17.1 (13.1) | 14.7 (8.0) | 12.9 (7.7) |
| Hyperlipidemia | 22.7 (19.4) | 26.9 (23.0) | 29.9 (17.3) | 26.4 (15.8) |
| Hypertension | 34.1 (25.8 | 40.3 (29.2) | 37.1 (16.4) | 32.1 (13.8) |
| Ischemic vascular disease | 2.7 (2.8) | 3.8 (5.2) | 4.9 (7.2) | 4.7 (6.2) |
| Current smoker | 13.7 (12.6) | 16.4 (15.4) | 9.4 (5.9) | 7.6 (4.7) |
| Two or more conditions | 27.2 (20.8) | 32.3 (25.6) | 28.2 (15.0) | 25.0 (14.0) |
Notes:
Analysis of Variance (ANOVA) p-value =0.0009. Duncan multiple range tests indicate that, of the charts sampled at each practice, mean age was significantly higher in patients with office visits in p1 and p2 than those with visits in e1 and e2.
ANOVA p-value = 0.0038. Duncan multiple range tests indicate that, of the charts sampled, the mean number of office visits per patient per practice was significantly lower in period e2 than in all other periods.
ANOVA p-value = 0.0028. Duncan multiple range tests indicate that, of the charts sampled, the mean number of current smokers per practice was significantly greater in period p2 than in periods e1 and e2.
Practice and Patient Panel Characteristics
| Number of practices | 35 | - | 47 | - |
| Percent of practices with one site | 85.7 | - | 79.1 | - |
| Number of providers | 3.0 | (1–40) | 3.5 | (1–21) |
| Full-time equivalent (FTE) | 3.0 | (0.7–44.8) | 4.1 | (1–63) |
| Months using EHR, as of 1/1/2010 | 20.5 | (15.2–28.5) | 19.2 | (11.1–28.4) |
| Percent Medicaid patients | 33.4 | (0–85) | 36.6 | (0–86) |
| Percent uninsured patients | 3.6 | (0–15) | 4.7 | (0–24.3) |
| Adult patient panel size | 1000 | (105–4273) | - | |
| Percent female | 60.3 | (47.7–81.1) | - | |
| 18–44 | 41.5 | (15.3–66.9) | - | |
| 45–64 | 42.7 | (26.9–58.6) | - | |
| 65–75 | 16.1 | (4.03–38.4) | - | |
| Diabetes | 13.4 | (0–38.4) | - | |
| Hyperlipidemia | 21.4 | (0–64.9) | - | |
| Hypertension | 32.7 | (3.4–76.5) | - | |
| Ischemic vascular disease | 6.9 | (0–29.6) | - | |
| Current smoker | 8.1 | (0.3–21.7) | - | |
Note:
Totals do not add up to 100% due to rounding.
Figure 1.Change in Population Level Performance Rates on Clinical Quality Measures
Comparison of Practice Performance Rates During the Second Pre-EHR Period (p2) and Each Post-EHR Period
| 25.6 | (17.3) | 24 | 23 (96%) | 23 (96%) | |
| 48.3 | (15.4) | 27 | 23 (85%) | 27 (100%) | |
| 65.0 | (42.0) | 31 | 18 (58%) | 23 (74%) | |
| 78.9 | (20.5) | 30 | 10 (33%) | 16 (53%) | |
| 80.3 | (8.6) | 26 | 24 (92%) | 26 (100%) | |
| 67.4 | (17.7) | 23 | 14 (61%) | 20 (87%) | |
| 45.2 | (15.0) | 4 | 4 (100%) | 4 (100%) | |
| 62.3 | (34.5) | 31 | 23 (74%) | 25 (81%) | |
| 20.4 | (19.8) | 10 | 7 (70%) | 7 (70%) | |
Notes:
On average, the end of e1 was 11 months after EHR go-live, and the end of e2 was 17 months after EHR go-live.
BP: Blood pressure; DM: Diabetes Mellitus; GP: General population; HbA1c: Hemoglobin A1c; HLP: Hyperlipidemia; HTN: Hypertension; IVD: Ischemic vascular disease; LDL: Low density lipoprotein
Number of Quality Measures for Which Qualified Practices Equaled or Exceeded Their Performance in the Second Pre-EHR Period (p2), by Post-EHR Period
| 1 | 31 | 31 (100%) | 31 (100%) |
| 2 | 31 | 31 (100%) | 31 (100%) |
| 3 | 30 | 29 (97%) | 30 (100%) |
| 4 | 30 | 25 (83%) | 28 (93%) |
| 5 | 26 | 15 (58%) | 22 (85%) |
| 6 | 25 | 10 (40%) | 18 (72%) |
| 7 | 22 | 5 (23%) | 9 (41%) |
| 8 | 10 | 1 (10%) | 3 (30%) |
| 9 | 2 | 0 (0%) | 0 (0%) |
Note:
On average, the end of the first post-EHR period (e1) was 11 months after EHR go-live, and the end of the second post-EHR period (e2) was 17 months after EHR go-live
Measure Specifications
| Patients 18+ years with ischemic vascular disease or 40+ with diabetes | Taking aspirin or other antithrombotic therapy | National Quality Forum (NQF) 0631 | |
| Patients 18–75 years with hypertension with or without diabetes | Without diabetes: Systolic <140 mmHg, Diastolic <90 mmHg | NQF 0018 | |
| Patients 18+ years | BMI recorded in past 24 months | NQF 1690 | |
| General population: Male (35+ years) or female (45+) patients with no prior diagnosis | General population: Total cholesterol and/or Low Density Lipids (LDL) tested in the past 5 years | NQF 0064 (DM); 0074 (IVD/CAD) | |
| General population: Male (35+ years) or female (45+) patients with no prior diagnosis and total cholesterol and/ or Low Density Lipids (LDL) tested in the past 5 years | General population: LDL <160 mg/ dL or total cholesterol <240 mg/dL | NQF 0064 (DM); 0074 (IVD/CAD) | |
| Patients 18–75 years with diabetes and hemoglobin A1c tested in the past 6 months | HbA1c level <7% | ||
| Patients 18–75 years with diabetes | HbA1c test recorded in the past 6 months | NQF 0057 | |
| Patients 18+ years with a “current smoker” smoking status | Smoking cessation intervention (Rx or counseling) received in the past 12 months | NQF 0028B | |
| Patients 18+ years | Smoking status recorded in the past 12 months | NQF 0028A |
| Antithrombotic Therapy | (+) | 6 | 18.1 | (11.8) | (+) | 6 | 63.9 | (16.5) |
| (+) | 6 | 69.4 | (11.2) | |||
|
| (+) | 4 | 66.7 | (23.6) | ||||||||||||
| 24 | 25.63 | (17.3) | (0) | 17 | 25.4 | (14.6) | (0) | 17 | 41.9 | (16.4) | (0) | 13 | 48.1 | (18.0) | ||
| (−) | 1 | 75.5 | (N/A) | (−) | 1 | 42.9 | (N/A) |
| (−) | 1 | 45.0 | (N/A) | ||||
| Blood Pressure Control | (+) | 3 | 34.7 | (30.0) | (+) | 3 | 62.0 | (17.8) |
| (+) | 2 | 63.8 | (19.5) | |||
| (0) | 1 | 65.5 | (N/A) | |||||||||||||
|
| (+) | 6 | 69.1 | (11.6) | ||||||||||||
| 27 | 48.33 | (15.4) | (0) | 20 | 47.1 | (11.0) | (0) | 20 | 47.7 | (10.9) | (0) | 14 | 53.2 | (7.5) | ||
|
| (0) | 4 | 50.5 | (14.0) | ||||||||||||
| (−) | 4 | 64.6 | (12.1) | (−) | 4 | 28.2 | 12.8 | |||||||||
| Body Mass Index Recorded | (+) | 8 | 9.8 | (19.0) | (+) | 8 | 72.7 | (21.9) |
| (+) | 8 | 85.3 | (13.4) | |||
|
| (+) | 4 | 75.3 | (28.8) | ||||||||||||
| 31 | 64.97 | (42.0) | (0) | 10 | 71.9 | (39.7) | (0) | 10 | 74.6 | (34.0) | (0) | 6 | 97.3 | (2.5) | ||
|
| (+) | 1 | 94.2 | (N/A) | ||||||||||||
| (0) | 4 | 85.5 | (6.6) | |||||||||||||
| (−) | 13 | 93.6 | (6.8) | (−) | 13 | 47.9 | (30.5) | (−) | 8 | 48.2 | (35.6) | |||||
| Cholesterol Testing |
| (+) | 3 | 58.6 | (38.2) | |||||||||||
| 30 | 78.87 | (20.5) | (0) | 10 | 60.4 | (22.0) | (0) | 10 | 55.1 | (19.4) | (0) | 7 | 68.7 | (6.2) | ||
|
| (+) | 1 | 68.4 | (N/A) | ||||||||||||
| (0) | 5 | 82.0 | (10.6) | |||||||||||||
| (−) | 20 | 88.1 | (12.0) | (−) | 20 | 41.9 | (22.9) | (−) | 14 | 54.8 | (24.0) | |||||
| Cholesterol Control | (+) | 2 | 64.3 | (2.6) | (+) | 2 | 86.3 | (2.9) |
| (+) | 1 | 89.7 | (N/A) | |||
| (0) | 1 | 77.3 | (N/A) | |||||||||||||
| 26 | 80.32 | (8.6) | (0) | 22 | 81.3 | (7.7) | (0) | 22 | 83.9 | (6.9) |
| (0) | 22 | 82.4 | (6.8) | |
|
| (0) | 2 | 74.7 | (2.5) | ||||||||||||
| (−) | 2 | 85.4 | (2.3) | (−) | 2 | 64.6 | (3.0) | |||||||||
| Hemoglobin A1c Testing | (+) | 1 | 30.8 | (N/A) | (+) | 1 | 76.9 | (N/A) |
| (+) | 1 | 80.0 | (N/A) | |||
| 23 | 67.43 | (17.7) | (0) | 13 | 62.9 | (14.8) | (0) | 13 | 53.8 | (17.0) |
| (0) | 13 | 71.5 | (14.1) | |
|
| (0) | 6 | 74.8 | (10.6) | ||||||||||||
| (−) | 9 | 78.0 | (14.2) | (−) | 9 | 31.1 | (19.8) | (−) | 3 | 42.4 | (27.2) | |||||
| Hemoglobin A1c Control | 4 | 45.21 | (15.0) | (0) | 4 | 45.2 | (15.0) | (0) | 4 | 43.3 | (15.8) |
| (0) | 4 | 32.3 | (13.5) |
| Smoking Status Recorded | (+) | 16 | 40.9 | (33.3) | (+) | 16 | 86.8 | (13.6) |
| (+) | 13 | 90.1 | (10.5) | |||
| (0) | 3 | 82.4 | (16.1) | |||||||||||||
|
| (+) | 1 | 68.8 | (N/A) | ||||||||||||
| 31 | 62.27 | (34.5) | (0) | 7 | 83.6 | (20.0) | (0) | 7 | 85.1 | (14.8) | (0) | 6 | 93.0 | (9.0) | ||
|
| (+) | 1 | 97.5 | (N/A) | ||||||||||||
| (0) | 1 | 96.5 | (N/A) | |||||||||||||
| (−) | 8 | 86.5 | (14.3) | (−) | 8 | 55.9 | (17.6) | (−) | 61.7 | (14.7) | ||||||
| Smoking Cessation Intervention | (+) | 1 | 15.4 | (N/A) | (+) | 1 | 89.5 | (N/A) |
| (+) | 1 | 90.0 | (N/A) | |||
|
| (+) | 1 | 81.8 | (N/A) | ||||||||||||
| 10 | 20.36 | (19.8) | (0) | 6 | 9.2 | (12.1) | (0) | 6 | 3.2 | (7.1) | (0) | 6.1 | (10.5) | |||
| (−) | 1 | 0.0 | (N/A) | |||||||||||||
|
| (0) | 1 | 14.3 | (N/A) | ||||||||||||
| (−) | 3 | 44.4 | (12.2) | (−) | 3 | 1.5 | (2.5) | (−) | 2 | 0.0 | (0.0) | |||||
To be included in this analysis, practices needed to have a minimum of 10 patients qualifying for an individual measure in each of the three time periods
(+): practice performance significantly (p<0.05) improved compared to p2
(0): practice performance did not significantly change compared to p2
(−): practice performance significantly (p<0.05) declined compared to p2